Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
A phase I trial: Dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection
Gordon L. Phillips
, Steven H. Bernstein
, Jane L. Liesveld
,
Camille N. Abboud
, Michael W. Becker
, Louis S. Constine
, J. J. Ifthikharuddin
, John E. Loughner
, Laurie A. Milner
, David H. Vesole
, Jonathan W. Friedberg
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Research output
:
Contribution to journal
›
Article
›
peer-review
6
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'A phase I trial: Dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Dose Escalation
100%
Cytarabine
100%
Cytoprotection
100%
Etoposide
100%
Amifostine
100%
Melphalan
100%
Phase I Trial
100%
Lymphoma Patients
33%
Overall Survival
16%
Dose-limiting Toxicity
16%
Phase I Study
16%
Maximum Tolerated Dose
16%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
16%
Phase II Trial
16%
Accruals
16%
Carmustine
16%
Cytoprotectant
16%
Safe Dose
16%
Melphalan Dose
16%
Medicine and Dentistry
Cytarabine
100%
Cytoprotection
100%
Etoposide
100%
Carmustine
100%
Amifostine
100%
Melphalan
100%
Phase I Trials
100%
Overall Survival
12%
Cytoprotective Agent
12%
Phase II Trials
12%
Autologous Hematopoietic Stem Cell Transplantation
12%